期刊文献+

比较围手术期应用度他雄胺和非那雄胺对经尿道前列腺电切术出血量的影响 被引量:12

Effect of perioperative use of dutasteride and finasteride on bleeding volume in transurethral prostatectomy
下载PDF
导出
摘要 目的比较围手术期应用度他雄胺和非那雄胺对经尿道前列腺电切术出血量的影响,为临床提供指导意义。方法将确诊的90例前列腺增生患者随机分成度他雄安组、非那雄胺组、对照组3组。度他雄安组、非那雄胺组术前及术后均口服药物1周,剂量为安福达0.5mg/次;非那雄胺组术前及术后均口服非那雄胺1周,5mg/次;对照组术前术后未给予任何药物,患者均经同一手术组医师使用等离子电切系统进行手术。对3组患者术中出血量、手术时间、术后膀胱冲洗液的量等进行比较。结果所有患者均顺利完成手术,效果满意,围手术期间均未发现药物副作用。3组患者术前、术后血红蛋白差值分别为(-1.29±0.81、-1.25±0.68、-1.83±1.25)g/L;血细胞压积差值分别为(-5.67±2.58、-6.34±2.89、-6.50±2.40)L/L;3组手术时间两者分别为(58.4±19.5、57.62±21.33、55.62±23.76)min;术后膀胱冲洗液量分别为(18.33±2.35、19.25±3.20、25.35±1.98)L,均有统计学差异(P<0.05)。度他雄安组术后膀胱冲洗液量少于非那雄胺组(P<0.05),但在手术出血量、手术时间两者比较无明显差异(P>0.05)。结论围手术期应采用非那雄胺或度他雄胺均可减少前列腺增生患者术中及术后出血量,缩短手术时间、减少术后膀胱冲洗液量,是有效、安全的,值得临床推广应用。 Objective To compare the effect of perioperative use of dutasteride and finasteride on the bleeding volume in transurethral prostatectomy.Methods A total of 90 confirmed benign prostate hyperplasia(BPH)cases were randomly divided into dutasteride group,finasteride group and control group.Patients in dutasteride group and finasteride group took dutasteride or finasteride 0.5 mg orally once a day for 1 week before operation and1 week after operation.Patients in the control group did not take any drug.All patients underwent transurethral plasmakinetic prostatectomy(TUPKP)by the same surgical team using the Gyrus F27 resectoscope.Intraoperative blood loss,operation time and lavage fluid volume were compared between the three groups.Results All operations were successful,and none patients treated with dutasteride and finasteride reported any side effects.The preoperative and postoperative hemoglobin of the dutasteride group,finasteride group and control group was(-1.29±0.81,-1.25±0.68,-1.83±1.25)g/L,the haematocrit was(-5.67±2.58、-6.34±2.89、-6.50±2.40)L/L,the operation time was(58.4±19.5,57.62±21.33,55.62±23.76)min,postoperative bladder lavage fluid volume was(18.33±2.35,19.25±3.20,25.35±1.98)mL.There were statistically significant differences(all P〈0.05).The postoperative bladder lavage fluid volume of the dutasteride was less than that of the finasteride group(P〈0.05),but there was no difference in blood loss and operation time(P〈0.05).Conclusion Both finasteride and dutasteride can reduce intraoperative and postoperative blood loss in patients with prostatic hyperplasia,shorten the operation time,and reduce the lavage fluid volume.They are worthy of clinical application.
出处 《现代泌尿外科杂志》 CAS 2015年第12期867-870,共4页 Journal of Modern Urology
关键词 非那雄胺 度他雄胺 前列腺增生 出血量 finasteride dutasteride benign prostatic hyperplasia(BPH) bleeding volume
  • 相关文献

参考文献15

  • 1PASTORE AL, MARIANI S, BARRESE F, et al. Transure- thral resection of prostate and the role o{ pharmacological treat- ment with dutasteride in decreasing surgical blood loss[J]. J En- dourol,2013,27(1) : 68-70.
  • 2BUSETTO GM, GIOVANNONE R, ANTONINI G, et al. Short-term pretreatment with a dual 5a-reductase inhibitor be- fore bipolar transurethral resection of the prostate (B-TURP) : evaluation of prostate vaseularity and decreased surgical blood loss in large prostates[J]. BJU Int, 2015,116(1) :117-123.
  • 3ANTONIO LUIG PASTORE, SIMONE MARIAN1, FRANCESCO BARRESE,et al. Transurethral resection of pros- tate and the role of pharmacological treatment with dutasteride in decreasing surgical blood loss[J]. J Endourol, 2013,27 : 68-70.
  • 4刘宇,侯铁汉,姜华茂,冯艳红,张莉.术前应用非那雄胺对经尿道前列腺电切术手术效果的影响[J].山东医药,2013,53(26):22-24. 被引量:7
  • 5FAN Y, HU S, LIU J,et al. Low intraprostatc DHT promotes the infiltration of CD8+ T ceils in BPH tissues via modulation of CCL5 seeretion[J]. Mediators Inflamm, 2014,14 : 397-815.
  • 6鲍镇美.睾丸切除对前列腺血流的影响[J].中华泌尿外科杂志,2001,22(9):575-576. 被引量:3
  • 7MULLER RL, GERBER L. MOREIRA DM, et al. Obesity is associated with increased prostate growth and attenuated pros- tate volume reduction by dutasteride[J]. Eur Urol, 201S, 63 (6) : 1115 -1121.
  • 8KEATING GM. Dutasteride/tamsulosin: in benign prostatic hyperplasia. Drugs Aging[J]. 2012,29(5):405-419.
  • 9FENTER TC, DAVIS EA, SHAH MB, et al. Dutasteride v s finasteride: Assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged or 65 years[J]. Am J Manag Care,2008,14 (5 supp 1 2) : 154-159.
  • 10LOKE YK, HO R, SMITH M,et al. Systematic review evalua- ting cardiovascular events of the 5-alpha reducta seinhibitor dutasteride[J]. J Clin Pharm Ther,2013, 38(5):405-415.

二级参考文献26

  • 1许云飞.多沙唑嗪、非那雄胺及其联合应用在BPH临床进展中的长期疗效[J].中华男科学杂志,2006,12(12):1149-1150. 被引量:1
  • 2Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology, 2002, 60(3) : 434-441.
  • 3Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology, 2004, 63(4) : 709-715.
  • 4Issa MM, Runken MC, Grogg AL, et al. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: Dutasteride versus finasteride. Am J Manag Care, 2007, 13 ( Suppl 1 ) : S10-S16.
  • 5Fenter TC, Davis EA, Shah MB, et al. Dutasteride vs finasteride: Assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or = 65 years. Am J Manag Care, 2008, 14(5 suppl 2) : s154-s159.
  • 6Kaplan SA, McConnell JD, Roehrtom CG, et al. Combination therapy with doxazosin and finastefide for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol, 20(16,175(1) : 217-221.
  • 7Roehrbom CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol, 2010, 57( 1 ) : 123-131.
  • 8Barkin J, Roehrbom CG, Siami P, et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int, 2009 , 103(7) : 919-926.
  • 9Tsukamoto T, Endo Y, Narita M. Assessment of recommended dose of dutasteride on Japanese men with benign prostatic hyperplasia: A randomized, double-blind, placebo-controlled, parallel-group, dose response study. Hinyokika Kiyo, 2009, 55(4) : 209-214.
  • 10Schulman C, Pommerville P, Heifner K, et al. Long-term therapy with the dual 5alpha- reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia. BJU Int, 2006, 97(1): 73-79.

共引文献31

同被引文献81

引证文献12

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部